← Back to Search

Norepinephrine Transporter Blocker

atomoxetine for Neurogenic Orthostatic Hypotension (NETAF Trial)

Phase 2
Waitlist Available
Led By Horacio Kaufmann, MD
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 to week 4
Awards & highlights

NETAF Trial Summary

This trial will study whether atomoxetine is an effective drug for treating symptoms associated with neurogenic orthostatic hypotension in patients with autonomic failure.

Eligible Conditions
  • Neurogenic Orthostatic Hypotension

NETAF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 to week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0 to week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hypotension, Orthostatic
Secondary outcome measures
Change in Blood Pressure
Change in Heart Rate (HR)

NETAF Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: atomoxetineActive Control1 Intervention
atomoxetine capsules 10 mg or 18 mg
Group II: placeboPlacebo Group1 Intervention
placebo capsules

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
850 Previous Clinical Trials
669,079 Total Patients Enrolled
NYU Langone HealthOTHER
1,358 Previous Clinical Trials
816,765 Total Patients Enrolled
Horacio Kaufmann, MDPrincipal InvestigatorNYU Langone Medical Center
9 Previous Clinical Trials
1,011 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are enrolled in this clinical experiment?

"Currently, this research trial is not accepting new participants. It was first published on the 29th of August in 2016 and last updated on the 22nd of August 2022. For those looking for alternatives, 115 clinical trials related to hypotension are actively enrolling patients as well as 12 studies centred around atomoxetine."

Answered by AI

Does this trial accept individuals aged fifty and above as participants?

"Patients between the ages of 40 and 80 are eligible to join this clinical trial. Additionally, 12 studies designed for participants under 18 years old have been conducted while 100 studies with patients over 65 exist."

Answered by AI

Is there still an opportunity for enrolment in this research endeavor?

"Unfortunately, this trial is not taking on patients at the moment. It was first published August 29th 2016 and last updated on 8/22/2022. On the other hand, there are 115 clinical trials searching for volunteers with hypotension and 12 studies looking to enroll participants that take atomoxetine."

Answered by AI

Might I be a suitable candidate for this research endeavor?

"In order to be part of this study, interested participants should have low blood pressure and meet the age criteria between 40-80 years old. The total number of patients accepted will amount to 48 individuals."

Answered by AI

Has the FDA sanctioned atomoxetine for use in patients?

"Data on atomoxetine's safety, but not efficacy, has been collected in a Phase 2 trial. As such, this drug was awarded an estimation of 2 for its overall safety profile."

Answered by AI

What other trials have been conducted to assess the efficacy of atomoxetine?

"Initially, atomoxetine was researched at Vanderbilt University Autonomic Dysfunction Center in 1997. Since then, 18383 trials have been completed and there are currently 12 active clinical studies mainly located in New york City."

Answered by AI
~6 spots leftby Mar 2025